drugset / Trial / NCT01318122
Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and Thiazolidine administered once daily (QD) for 40 consecutive weeks in participants who completed a phase 2/3 Thiazolidine add on study.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alogliptin | Unknown | 12.5 mg | Oral |
| Comparator | Alogliptin | Unknown | 25 mg | Oral |
| Comparator | Pioglitazone | Small molecule | 15 mg | Oral |
| Comparator | Pioglitazone | Small molecule | 30 mg | Oral |